Actavis and Medicines360 announced the launch of Liletta (levonorgestrel-releasing intrauterine system) 52mg for the prevention of pregnancy for up to 3 years.

RELATED: IUD Approval Gives Women New Long-Acting Birth Control Option 

Liletta was approved by the Food and Drug Administration (FDA) in February 2015 based on data from the ACCESS IUS (A Comprehensive Contraceptive Efficacy & Safety Study of an IUS) study. Liletta is placed in the uterus by a healthcare professional when it is reasonably certain that the woman is not pregnant. It can be removed by a healthcare professional at any time. 

Liletta works by slowly releasing levonorgestrel, a progestin. Several mechanisms for pregnancy prevention include: prevention of fertilization due to the thickening of the cervical mucus, which inhibits sperm passage through the cervix, and inhibition of sperm motility and function (capacitation), and alteration of the endometrium. 

Liletta is 32mm x 32mm in size and is packaged with an inserter in single unit cartons.

For more information call (800) 272-5525 or visit